Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Preparation for Single-Cell DNA Analysis


MSKCC Lab Combined Tapestri and Singulator 100 to Demonstrate Automated Core Extraction Workflow for Fast and Reliable Preparation of Nuclei for Single-Cell DNA Analysis

SOUTH SAN FRANCISCO, CA., April 19, 2022 /PRNewswire/ — Mission Bio, Inc., the pioneer of multi-omics analysis and high-throughput single-cell DNA, today announced a co-marketing partnership with S2 Genomics, Inc., a leading developer of automation solutions for laboratory for solid tissue processing for single-cell applications, to provide a unique streamlined workflow for solid tumor applications, from sample preparation to analysis. The automated nucleus extraction and analysis workflow has been validated by the laboratory of Christine A. Iacobuzio-DonahueMD, PhD, director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), who shared her findings Last week at the annual meeting of the American Association for Cancer Research (AACR).

Single-cell DNA analysis has transformed cancer research, supporting high-resolution insights into tumor heterogeneity that have led to a series of high profile publications on disease mechanisms. But the challenges are greater for solid tumor profiling, where existing preparation workflows often fail to produce enough cells or nuclei to provide meaningful results. To meet this challenge, Mission Bio launched last month its Tapestri Solution for Solid Tumor Research, including new pre-designed research panels for breast cancer and glioblastoma multiforme, and an improved bioinformatics analysis tool for single-cell copy number (CNV) variation. Researchers can now match S2 Genomics Singulator™ 100 automated dissociation technology of solid tissues into suspensions of single cells or nuclei with Tapestri in the same workflow for scalable, high throughput, efficient and reproducible tissue processing.

“We look forward to partnering with leading companies to address key sample preparation challenges in solid tumor research,” said Yan Zhang, PhD, CEO of Mission Bio. “As Dr. Iacobuzio-Donahue’s lab demonstrates, the Singulator 100 and Tapestri together provide a powerful solution for large-scale single-cell DNA sequencing in pancreatic cancer research and a variety of tissue types. “

“The Singulator 100 has been an important tool in enabling single-cell sequencing in solid tissues, but cancer researchers have not been able to interrogate DNA directly,” said John Baskin, Chief Strategy Officer of S2 Genomics. “Tapestri is the only commercial platform capable of analyzing DNA from a single cell, and we are excited to offer this single automated pipeline connecting cell and nucleus preparation to the microfluidics-based workflow of Tapestry.

To learn more about Mission Bio and the Tapestri platform, please visit missionbio.com.

About Mission Bio

Mission Bio is a life sciences company accelerating discovery and treatment for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time to market for new therapies, including innovative cell and gene therapies that open new pathways to health. Founded in 2014, Mission Bio has secured investments from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund and others.

The Company’s Tapestri platform gives researchers around the world the power to interrogate every molecule in a cell together, providing a comprehensive understanding of the activity of a single sample. Tapestri is the only commercial multi-omics platform capable of simultaneously analyzing DNA and proteins from the same sample at single-cell resolution. The Tapestri platform is used by customers at leading research centers, pharmaceutical companies and diagnostics companies around the world to develop treatments and eventually cures for cancer.

About S2 Genomics, Inc.

S2 Genomics, founded in 2016, is a leading developer of laboratory automation solutions for processing solid tissue for single-cell applications. S2 Genomics’ technology platforms integrate advanced fluidics, optics and biochemistry to produce automated sample preparation solutions for the single cell sequencing and cell biology markets, enabling discovery and innovation in research in life sciences, healthcare and agriculture.

For more information on S2 Genomics and the Singulator 100, visit www.S2Genomics.com.

Media Contact
Consort Partners for Mission Bio
[email protected]

SOURCE Mission Biography

Source link


About Author

Comments are closed.